酪氨酸激酶抑制剂时代非小细胞肺癌软脑膜转移患者的多学科管理
该回顾性研究纳入61例接受Ommaya储液囊植入、脑室腹腔分流或腰腹腔分流的非小细胞肺癌软脑膜转移患者,按影像学及诊断时序分为无脑转移、脑转移同时伴软脑膜转移和脑转移后软脑膜转移三亚型。中位总生存期8.1个月(范围0.2-70.0),脑转移后软脑膜转移组中位总生存期5.4个月,短于同时组5.5个月和无脑转移组11.6个月(p=0.019)。KPS评分≥70(HR 0.51;p=0.027)和分流植入(HR 0.41;p=0.032)为有利预后因素。
要点
- 61例患者中43例(70.5%)为EGFR突变,57例(93.4%)合并脑积水。
- 脑转移后软脑膜转移组中位总生存期5.4个月,短于同时组5.5个月和无脑转移组11.6个月(p=0.019)。
- KPS评分≥70(HR 0.51;p=0.027)和分流植入(HR 0.41;p=0.032)为有利预后因素。
核心结论
- 无脑转移的软脑膜转移患者生存结局(11.6个月)优于脑转移后软脑膜转移或脑转移同时伴软脑膜转移者。
- 积极的分流植入可能对软脑膜转移有利。
研究设计与样本
- 回顾性收集接受Ommaya储液囊植入、脑室腹腔分流植入或腰腹腔分流植入的非小细胞肺癌患者数据。
- 根据影像学表现及从非小细胞肺癌诊断至软脑膜转移的时间,分为无脑转移、脑转移同时伴软脑膜转移和脑转移后软脑膜转移三亚型。
- 采用Kaplan-Meier法分析总生存期,多因素Cox回归分析预后因素。
主要发现
- 共纳入61例软脑膜转移患者,中位总生存期8.1个月(范围0.2-70.0)。
- 43例(70.5%)患者为EGFR突变,其中42例(68.9%)为19-del或L858R突变,1例(1.6%)为G719A突变。
- 57例(93.4%)患者合并脑积水。
- 脑转移后软脑膜转移组KPS评分50,低于无脑转移组KPS评分80和同时组KPS评分70(p=0.003)。
- 脑转移后软脑膜转移组中位总生存期5.4个月,短于同时组5.5个月和无脑转移组11.6个月(p=0.019)。
关键数值与推荐
- KPS评分≥70(HR 0.51;p=0.027)和分流植入(HR 0.41;p=0.032)为有利预后因素。
- 脑转移后软脑膜转移组接受鞘内甲氨蝶呤的患者多于其他亚组(p<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Leptomeningeal metastasis (LM) is a challenging scenario in non-small cell lung cancer (NSCLC). Considering that outcomes of treatment modalities stratified by LM chronological patterns related to brain metastasis (BM) are lacking, the aim of this study was to evaluate outcomes and explore prognostic factors. METHODS: The authors retrospectively collected data of patients with NSCLC undergoing Ommaya reservoir implantation, ventriculoperitoneal shunt implantation, or lumboperitoneal shunt implantation. Based on radiographic findings and time from diagnosis of NSCLC to LM, the authors divided them into subtypes of LM as follows: LM without BM; LM concurrent with BM; or LM after BM. The Kaplan-Meier method was applied to analyze overall survival (OS) and multivariate Cox regression for prognostic factors. RESULTS: Sixty-one patients with LM were included, with a median OS of 8.1 (range 0.2-70.0) months. Forty-three (70.5%) patients had EGFR-mutant disease. Forty-two (68.9%) patients had 19-del or L858R mutation, and one (1.6%) patient had G719A mutation. Fifty-seven (93.4%) patients had hydrocephalus. Twenty-one (34.4%) patients received whole-brain radiotherapy before LM diagnosis, 3 (4.9%) patients underwent operation for BMs before LM diagnosis, and 42 (68.9%) patients received EGFR tyrosine kinase inhibitor (TKI) therapy before LM diagnosis. Eleven patients were treated with chemotherapy, 10 patients were treated with TKIs, and 32 patients were treated with chemotherapy combined with TKIs before LM diagnosis. Patients with LM after BM had lower Karnofsky Performance Status (KPS) scores (KPS score 50) than did those with LM without BM (KPS score 80) or LM concurrent with BM (KPS score 70; p = 0.003). More patients with LM after BM received intrathecal methotrexate than in the other subgroups (p < 0.001). The median OS was significantly shorter in the LM after BM than in the concurrent LM and BM and the LM without BM subgroups (5.4 vs 5.5 vs 11.6 months; p = 0.019). Cox regression revealed that a KPS score ≥ 70 (HR 0.51; p = 0.027) and shunt implantation (HR 0.41; p = 0.032) were favorable prognostic factors. CONCLUSIONS: Patients with NSCLC who had LM without BM had better survival outcomes (11.6 months) compared with those who had LM after BM or concurrent LM and BM. Aggressive shunt implantation may be favored for LM.
引用
- Chen KY, Wu SG, Lai DM, et al. Multidisciplinary management of patients with non-small cell lung cancer with leptomeningeal metastasis in the tyrosine kinase inhibitor era. J Neurosurg. 2022. PMID: 36208438. doi:10.3171/2022.8.JNS221175
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。